Albrecht Stoehr

3.9k total citations
97 papers, 1.6k citations indexed

About

Albrecht Stoehr is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Albrecht Stoehr has authored 97 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Infectious Diseases, 44 papers in Epidemiology and 41 papers in Hepatology. Recurrent topics in Albrecht Stoehr's work include Hepatitis C virus research (41 papers), HIV/AIDS drug development and treatment (30 papers) and HIV Research and Treatment (25 papers). Albrecht Stoehr is often cited by papers focused on Hepatitis C virus research (41 papers), HIV/AIDS drug development and treatment (30 papers) and HIV Research and Treatment (25 papers). Albrecht Stoehr collaborates with scholars based in Germany, United States and Estonia. Albrecht Stoehr's co-authors include Andreas Plettenberg, Christian Hoffmann, Helmut Albrecht, Hans‐Jürgen Stellbrink, Eva Wolf, Heinz‐August Horst, Christian Eggers, Thomas Buhk, Chloe Orkin and Olaf Degen and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Albrecht Stoehr

90 papers receiving 1.5k citations

Peers

Albrecht Stoehr
Pilar Miralles Spain
Mark Oette Germany
Marilia Rita Pinzone Italy
David J. Riedel United States
Peter J. Piliero United States
M Youle United Kingdom
Sarah H. Cheeseman United States
Eleanor Wilson United States
Rosalyn E. Stahl United States
Atsushi Ajisawa Japan
Pilar Miralles Spain
Albrecht Stoehr
Citations per year, relative to Albrecht Stoehr Albrecht Stoehr (= 1×) peers Pilar Miralles

Countries citing papers authored by Albrecht Stoehr

Since Specialization
Citations

This map shows the geographic impact of Albrecht Stoehr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albrecht Stoehr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albrecht Stoehr more than expected).

Fields of papers citing papers by Albrecht Stoehr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albrecht Stoehr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albrecht Stoehr. The network helps show where Albrecht Stoehr may publish in the future.

Co-authorship network of co-authors of Albrecht Stoehr

This figure shows the co-authorship network connecting the top 25 collaborators of Albrecht Stoehr. A scholar is included among the top collaborators of Albrecht Stoehr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albrecht Stoehr. Albrecht Stoehr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rossol, S., Christian Krauth, Peter Buggisch, et al.. (2022). Real‐world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R). Zeitschrift für Gastroenterologie. 61(5). 489–503. 3 indexed citations
2.
Crowell, Trevor A., Haoyu Qian, Carsten Tiemann, et al.. (2021). Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort. AIDS Research and Therapy. 18(1). 52–52. 3 indexed citations
3.
Hentrich, Marcus, Mark Bower, Gedske Daugaard, et al.. (2021). Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. Cancer. 128(2). 260–268. 2 indexed citations
4.
Bickel, Markus, Christian Hoffmann, Eva Wolf, et al.. (2020). High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study. Infection. 48(3). 453–461. 10 indexed citations
5.
Schommers, Philipp, Daniel Gillor, Marcus Hentrich, et al.. (2018). Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 103(5). 857–864. 22 indexed citations
6.
7.
Sabranski, Michael, Albrecht Stoehr, Andreas Plettenberg, et al.. (2014). Everything fine so far? Physical and mental health in HIV‐infected patients with virological success and long‐term exposure to antiretroviral therapy. Journal of the International AIDS Society. 17(4S3). 19673–19673. 17 indexed citations
8.
Manns, Michael P., Edward Gane, M. Rodríguez‐Torres, et al.. (2012). Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. Hepatology. 56(3). 884–893. 46 indexed citations
9.
Duprez, Daniel, Russell P. Tracy, Lewis H. Kuller, et al.. (2011). N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS. 25(5). 651–657. 28 indexed citations
10.
11.
Hoffmann, Christian, Martin Ernst, P Meyer, et al.. (2007). Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clinical Microbiology and Infection. 13(5). 510–515. 22 indexed citations
12.
Schmutz, Guenther, Mark Nelson, Thomas A. Lutz, et al.. (2006). Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS. 20(15). 1951–1954. 66 indexed citations
13.
Hoffmann, Christian, Kai Uwe Chow, Eva Wolf, et al.. (2004). Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus‐associated Hodgkin's disease. British Journal of Haematology. 125(4). 455–462. 66 indexed citations
14.
Hoffmann, Christian, Eva Wolf, Gerd Fätkenheuer, et al.. (2003). Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 17(10). 1521–1529. 90 indexed citations
15.
Plettenberg, Andreas, Albrecht Stoehr, & W. Meigel. (2001). Milzbrand Der Erreger, das Krankheitsbild und der mögliche Einsatz als biologische Waffe. Der Hautarzt. 52(12). 1075–1078. 1 indexed citations
16.
Zöllner, Bernhard, Albrecht Stoehr, Andreas Plettenberg, et al.. (2000). In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy — a clinical note. Journal of Clinical Virology. 17(3). 183–188. 9 indexed citations
17.
Richter, Elvira, et al.. (2000). Detection, identification, and treatment of a novel, non-cultivable Mycobacterium species in an HIV patient. AIDS. 14(11). 1667–1668. 13 indexed citations
18.
Plettenberg, Andreas, et al.. (1997). Increased Risk for Opportunistic Infections during Chemotherapy in HIV-lnfected Patients with Kaposi’s Sarcoma. Dermatology. 194(3). 234–237. 4 indexed citations
19.
Bogner, Johannes R., Sabine Rüsch–Gerdes, R Baumgaŕten, et al.. (1997). Patterns of Mycobacterium avium Culture and PCR Positivity in Immunodeficient HIV-infected Patients: Progression from Localized to Systemic Disease. Scandinavian Journal of Infectious Diseases. 29(6). 579–584. 6 indexed citations
20.
Stellbrink, Hans‐Jürgen, Helmut Albrecht, Andreas Plettenberg, et al.. (1993). Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients. European Journal of Clinical Microbiology & Infectious Diseases. 12(8). 618–621. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pilar Miralles Breakdown of academic impact, for papers by Mark Oette Breakdown of academic impact, for papers by Marilia Rita Pinzone Breakdown of academic impact, for papers by David J. Riedel Breakdown of academic impact, for papers by Peter J. Piliero Breakdown of academic impact, for papers by M Youle Breakdown of academic impact, for papers by Sarah H. Cheeseman Breakdown of academic impact, for papers by Eleanor Wilson Breakdown of academic impact, for papers by Rosalyn E. Stahl Breakdown of academic impact, for papers by Atsushi Ajisawa
Rankless by CCL
2026